The slow and incomplete correction of lipids by CFTR correctors in CF HBEC-ALI seems contrary to the general assumption that rescuing 10–20% of normal CFTR activity measured as forskolin-stimulated short circuit current would be sufficient to alleviate clinical symptoms, including downstream effects on inflammation and tissue remodeling. The gene discussed is CFTR; the disease is acute respiratory distress syndrome.